Publications by authors named "Heike Reinhardt"

Claim this Profile
I
Ixazomib-lenalidomid-dexamethasone (IRd) in relapsed refractory multiple myeloma (RRMM)-multicenter real-world analysis from Germany and comparative review of the literature.
Hanna Löffler, Magdalena Braun, Heike Reinhardt, Amelie Rösner, Gabriele Ihorst

Ann Hematol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing individualized therapy decision-making in multiple myeloma (MM): integration and impact of the Revised Myeloma Comorbidity Index in the MM-tumor board.
Esther Dreyling, Gabriele Ihorst, Heike Reinhardt, Jan Räder, Maximilian Holler

Ann Hematol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comorbidity indices for prognostic evaluation in multiple myeloma: a comprehensive evaluation of the Revised Myeloma Comorbidity Index and other comorbidity indices with pro- and retrospective applications.
Katja Schoeller, Gabriele Ihorst, Heike Reinhardt, Maximilian Holler, Sophia Scheubeck

Haematologica· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An objective assessment in newly diagnosed multiple myeloma to avoid treatment complications and strengthen therapy adherence.
Maximilian Holler, Gabriele Ihorst, Heike Reinhardt, Amelie Rösner, Magdalena Braun

Haematologica· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the prognostic significance of 5 comorbidity scores and 12 functional tests in a prospective multiple myeloma patient cohort.
Sophia Scheubeck, Gabriele Ihorst, Katja Schoeller, Maximilian Holler, Mandy-Deborah Möller, Heike Reinhardt

Cancer· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors.
Laura Gengenbach, Giulia Graziani, Heike Reinhardt, Amelie Rösner, Magdalena Braun

Cancers (Basel)· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ruxolitinib.
Stefanie Ajayi, Heiko Becker, Heike Reinhardt, Monika Engelhardt, Robert Zeiser

Recent Results Cancer Res· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pomalidomide.
Monika Engelhardt, Stefanie Ajayi, Heike Reinhardt, Stefan Jürgen Müller, Sandra Maria Dold

Recent Results Cancer Res· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avoiding chemotherapy prescribing errors: Analysis and innovative strategies.
Heike Reinhardt, Petra Otte, Alison G Eggleton, Markus Ruch, Stefan Wöhrl

Cancer· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GFR estimation in lenalidomide treatment of multiple myeloma patients: a prospective cohort study.
Andrea Schmidts, Julian Grünewald, Martina Kleber, Evangelos Terpos, Gabriele Ihorst, Heike Reinhardt

Clin Exp Nephrol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Navigating the changing multiple myeloma treatment landscape: clinical practice patterns of MM patients treated in- and outside German DSMM study group trials.
Laura Gengenbach, Heike Reinhardt, Gabriele Ihorst, Stefanie Ajayi, Sandra Maria Dold

Leuk Lymphoma· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osteoprotective medication in the era of novel agents: a European perspective on values, risks and future solutions.
Monika Engelhardt, Georg W Herget, Giulia Graziani, Gabriele Ihorst, Heike Reinhardt

Haematologica· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients.
Monika Engelhardt, Anne-Saskia Domm, Sandra Maria Dold, Gabriele Ihorst, Heike Reinhardt

Haematologica· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Paving the Way for Dose Banding of Chemotherapy: An Analytical Approach.
Heike Reinhardt, Rainer Trittler, Alison G Eggleton, Stefan Wöhrl, Thomas Epting

J Natl Compr Canc Netw· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avoiding Errors in Chemotherapy.
Stefanie Ajayi, Heike Reinhardt, Magdalena Szymaniak-Vits, Monika Engelhardt

Dtsch Arztebl Int· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores.
Monika Engelhardt, Sandra Maria Dold, Gabriele Ihorst, Alexander Zober, Mandy Möller, Heike Reinhardt

Haematologica· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years.
Monika Engelhardt, Gabriele Ihorst, Ola Landgren, Milena Pantic, Heike Reinhardt

Haematologica· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pomalidomide.
Monika Engelhardt, Ralph Wäsch, Heike Reinhardt, Martina Kleber

Recent Results Cancer Res· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of iron overload vs iron deficiency in multiple myeloma: resembling or different from MDS--and stem cell transplant (SCT)--patients?
Christine König, Martina Kleber, Gabriele Ihorst, Anette Gropp, Heike Reinhardt

Clin Lymphoma Myeloma Leuk· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of the Freiburg Comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome.
Martina Kleber, Gabriele Ihorst, Barbara Gross, Bernd Koch, Heike Reinhardt

Clin Lymphoma Myeloma Leuk· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis